BAM
AXSM icon

Bosun Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Bosun Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,022
Closed -$211K – 87
2025
Q2 		$211K Buy
+2,022
New +$214K 0.06% 192

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bosun Asset Management's AXSM Position: Q3 2025 in Review

Bosun Asset Management sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 2,022 shares — an estimated $211K sold.

Bosun Asset Management first reported a position in AXSM in Q2 2025 and held it in 1 quarter. The position peaked at $211K in Q2 2025. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Bosun Asset Management reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bosun Asset Management sold 2,022 Axsome Therapeutics shares in Q3 2025, an estimated $211K.
  • Bosun Asset Management first reported a position in Axsome Therapeutics in Q2 2025 and held it in 1 quarter.
  • Bosun Asset Management's Axsome Therapeutics position peaked at $211K in Q2 2025.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Bosun Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.